Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of cancer
3.2.1.2 Growing adoption of chemotherapy
3.2.1.3 Technological advancements in treatment options
3.2.1.4 Rising government initiatives and funding
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Adverse effects of treatment
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis
3.8 Future market trends
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Granulocyte colony-stimulating factor therapy
5.3 Antibiotics
5.4 Granulocyte transfusion
5.5 Antifungals
5.6 Other treatment types
Chapter 6 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Branded
6.3 Biosimilars
Chapter 7 Market Estimates and Forecast, By Route of administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Parenteral
7.3 Oral
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Amgen Inc.
10.2 BeyondSpring Inc.
10.3 Biocon Biologics Inc.
10.4 Cellerant Therapeutics
10.5 Coherus BioSciences, Inc.
10.6 Evive Biotech
10.7 Kyowa Kirin Co., Ltd.
10.8 Novartis AG
10.9 Pfizer Inc.
10.10 Sanofi
10.11 Spectrum Pharmaceuticals
10.12 Teva Pharmaceutical Industries Ltd.
